Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GCGR | P47871 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 4/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MDH1 | P40925 | 1/20 | 0.37 |
| ▸ | MDH2 | P40926 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2657513 | 0.87 | LMNA (0.42) | LMNAGCGREGFRMRGPRX4MAPT | |
| SCHEMBL2655395 | 0.86 | GCGR (0.41) | LMNAGCGREGFRMRGPRX4MAPT | |
| SCHEMBL2655712 | 0.83 | LMNA (0.40) | LMNAGCGREGFRMRGPRX4MAPT | |
| SCHEMBL2654811 | 0.83 | GCGR (0.59) | GCGR | |
| SCHEMBL2654224 | 0.82 | L3MBTL1 (0.43) | GCGRMAPTGAAPPARDPPARA | |
| SCHEMBL2656365 | 0.79 | GCGR (0.40) | LMNAGCGRMRGPRX4MAPTGAA | |
| SCHEMBL5119133 | 0.79 | GCGR (0.44) | LMNAGCGRRPS6KB1PPARDKDM4E | |
| SCHEMBL2655393 | 0.78 | GCGR (0.57) | LMNAGCGREGFRRPS6KB1 | |
| SCHEMBL2657514 | 0.77 | GCGR (0.41) | LMNAGCGRMRGPRX4MAPTRPS6KB1 | |
| SCHEMBL2656363 | 0.76 | GCGR (0.53) | LMNAGCGRRPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076374-B2 | Used to treat diabetic and other glucagon related metabolic disorders such as obesity, hyperglycemia, atherosclerosis, ischemic heart disease, stroke, neuropathy, and wound healing; 3-{4-[1-Allyl-1-(4'-trifluoromethyl-biphenyl-4-yloxymethyl)-but-3-enyl]-benzoylamino}-propionic acid; | ELI LILLY AND COMPANY (US) | 2011-12-13 | — | — | US | disclosed |
| EP-1951659-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20080319074-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2008-12-25 | — | — | US | disclosed |
| EP-1951659-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | Eli Lilly & Company (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007114855-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319074-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | LMNA 3722/4885GCGR 2/4885EGFR 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.